Project description:To investigate changes to chromatin accessibility associated with resistance to lapatinib, we performed ATAC-seq on OE19 cells treated with 500 nM lapatinib for 1, 7 and 35 days and vehicle control (DMSO) for 1 day.
Project description:To investigate changes to gene expression associated with resistance to lapatinib, we performed ATAC-seq on OE19 cells treated with 500 nM lapatinib for 1, 7 and 35 days and vehicle control (DMSO) for 1 day.
Project description:ChIP-seq for PPARGC1A was performed in OE19 cells to identify genomic binding sites. Cells were treated with 500 nM lapatinib for 48 hours.
Project description:To investigate whether changes to chromatin accessibility associated with resistance to lapatinib are a stable or a reversible state, we treated OE19 cells with 500 nM lapatinib for 35 days and then withdrew lapatinib for 1, 2, 3 and 14 days. Control cells treated with DMSO for 1 day and 'resistant' cells treated with 500 nM lapatinib for 35 days were also sequenced.
Project description:ChIP-seq for HNF4A, PPARGC1A and H3K27ac was performed in OE19 cells to identify genomic binding sites. Cells were treated with DMSO or 500 nM lapatinib for 48 hours.
Project description:To determine genes regulated by the transcriptional co-activator PPARGC1A in OAC cells and whether PPARGC1A activity is altered by lapatinib we performed RNA-seq on OE19 cells treated with non-targeting siRNA or siRNA targeting PPARGC1A. 24 hours post-transfection, cells were also treated with either DMSO or 500 nM lapatinib for 24 hours.